![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>News & Press</title><link>https://itog.org/news/</link><description><![CDATA[ Read about recent events, essential information and the latest community news. ]]></description><lastBuildDate>Sun, 5 May 2024 23:34:54 GMT</lastBuildDate><pubDate>Fri, 16 Feb 2024 18:11:00 GMT</pubDate><copyright>Copyright © 2024 International Thyroid Oncology Group</copyright><atom:link href="http://itog.org/resource/rss/news.rss" rel="self" type="application/rss+xml"></atom:link><item><title>2023 Winter Annual Newsletter</title><link>https://itog.org/news/665268/</link><guid>https://itog.org/news/665268/</guid><description><![CDATA[<a href="https://itog.org/resource/resmgr/annual_newsletters_/itog_winter_2023_newsletter.pdf">2023 Annual Newsletter</a> Click here to view]]></description><category>News</category><pubDate>Fri, 16 Feb 2024 19:11:00 GMT</pubDate></item><item><title>ACCRU-ITOG-1504 Achieves Accrual Goal </title><link>https://itog.org/news/507695/</link><guid>https://itog.org/news/507695/</guid><description><![CDATA[<p><span face="Arial" style="color: #5b6770;"><strong><img alt="" src="https://cdn.ymaws.com/osumc.site-ym.com/resource/resmgr/people/haugen_b.jpg" style="width: 170px; height: 230px; vertical-align: top;" /> </strong></span></p><p><span face="Arial" style="color: #5b6770;"><strong>Congratulations </strong>to </span><span style="color: #5b6770;"><span style="color: #666666;">Principal Investigator: Bryan Haugen at The <span style="color: #5b6770;">University of Colorado Cancer Center</span> and his team for achieving </span><span style="color: #666666;">accrual goal of 60 ACCRU-ITOG-1504: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study. </span></span></p>]]></description><category>News</category><pubDate>Fri, 15 May 2020 20:16:56 GMT</pubDate></item><item><title> ITOG Robert F. Gagel Discovery Award Recipient Carmelo Nucera, MD</title><link>https://itog.org/news/500079/</link><guid>https://itog.org/news/500079/</guid><description><![CDATA[<span> </span>Please join us in congratulating the 2019 Robert F. Gagel ITOG Discovery Award Recipient, Carmelo Nucera, MD for his submission “Engineering a new mouse model of a thyroid-specific lincRNA in BRAFV600E papillary thyroid carcinoma.” <span> </span>]]></description><category>News</category><pubDate>Mon, 6 Apr 2020 20:54:21 GMT</pubDate></item><item><title> LOXO-292 demonstrates promising anti-tumor activity in RET-altered thyroid cancer</title><link>https://itog.org/news/500074/</link><guid>https://itog.org/news/500074/</guid><description><![CDATA[<p><span style="color: #5b6770;">ITOG member Dr. Lori Wirth recently presented progress on a Phase 1/2 study of LOXO-292 at the European Society for Medical Oncology (ESMO) Annual Congress in Barcelona, Spain. This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.</span></p><p><font color="#5b6770"><a href="https://itog.org/news/492648/Selpercatinib-LOXO-292-demonstrates-promising-anti-tumor-activity-in-RET-altered-thyroid-cancers.htm"><strong>Read More</strong></a></font></p><p><span style="color: #5b6770;"><a href="https://itog.org/news/492648/Selpercatinib-LOXO-292-demonstrates-promising-anti-tumor-activity-in-RET-altered-thyroid-cancers.htm"> </a></span></p><p><span style="color: #5b6770;"> </span></p>]]></description><category>News</category><pubDate>Mon, 6 Apr 2020 20:42:19 GMT</pubDate></item><item><title> ITOG Selumetinib Trial Achieves Accrual Goal!</title><link>https://itog.org/news/500071/</link><guid>https://itog.org/news/500071/</guid><description><![CDATA[<span> </span><br />ITOG Selumetinib Trial Achieves Accrual Goal!<br /><br />Congratulations to Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center and his team for achieving accrual goal of 60 for the <a href="https://clinicaltrials.gov/ct2/show/NCT02393690?term=selumetinib+ho&draw=2&rank=1">Selumetnib plus RAI for RAI-Avid Thyroid Cancer.</a><br />]]></description><category>News</category><pubDate>Mon, 6 Apr 2020 20:36:31 GMT</pubDate></item><item><title>2024 ITOG Annual Meeting: One of the very best</title><link>https://itog.org/news/474736/</link><guid>https://itog.org/news/474736/</guid><description><![CDATA[The 12th Annual Meeting of the International Thyroid Oncology Group was held in early May in New York City, New York, and was co-hosted by Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center (MSKCC). <div> </div><div>The Program Committee was comprised of several ITOG members, including Dr. Eric Sherman, Dr. Yariv Houvras, Dr. Alan Ho, Dr. Michael Tuttle, and Dr. David Pfister. This scientific meeting drew upon experts in cancer research from around the world to share inspiring research progress and to collaborate with colleagues. ITOG members presented their data on active clinical trials and basic science research while finalizing details for upcoming ITOG-sponsored clinical trials. Invited faculty provided their insights and research findings to prompt discussion of future directions for thyroid cancer research. </div><div><div>This year, meeting presentations were divided into six sessions covering topics in thyroid cancer research and treatment, ranging from “Immunotherapy” to “Anaplastic Cancer” to “Cancer Registries.” A new format this year involved the creation of task forces, each of which helped to select presenters and to moderate discussions following each session. The format also allowed for extra time, enabling participants to discuss presentations within each section. This extra time was intended to improve networking and collaboration. At the start of each day there was one Keynote speech, each setting the tone for the remainder of the</div><div> sessions. Dr. Jedd Wolchok gave an informative presentation on “Immune Checkpoint Blockade Combinations and Mechanisms” and Dr. James Fagin presented his findings on “Functional Genomic and Novel Therapeutic Vulnerabilities of Advanced Thyroid Cancer.” Both talks were informative and inspiring. </div><div> </div><div>This meeting also featured the first “Sunday Morning Fun Run” in Central Park, guided by running enthusiast, Dr. Yariv Houvras. Some attendees thought that the run started too early for a Sunday morning, though the exercise was generally well received. Many appreciated the effort to provide a healthy, bonding experience for attendees. </div></div><div> </div><div>The annual closing dinner on Saturday evening included a history of MSKCC, presented by Dr. Thomas Fahey. Dwight Vicks, ITOG co-founder and treasurer, then welcomed Donna LeBeau and Kimberly Caplea of the REACT (Research Education Action Cancer Thyroid) Foundation in recognition of the ITOG and REACT merger this past year. REACT is dedicated to creating awareness for thyroid cancer and raising funds to support research for new treatment options. Donna’s daughter and Kimberly’s sister, Michelle LeBeau, founded this public charity in 2011 after battling medullary thyroid cancer (MTC) for two years. ITOG and REACT recently joined forces to specifically focus on finding treatments for MTC. In Donna’s words, “ITOG is the preeminent organization that brings together leaders in the field to develop better treatments for all types of thyroid cancer, including MTC.” ITOG is most grateful to Donna and Kimberly for choosing ITOG to carry on Michelle’s legacy.</div><div> </div><div><div>The dinner also included poignant remarks from Rosie Sherman, the daughter of former ITOG Chair Dr. Steven Sherman, who shared her very personal experience with thyroid cancer. Her speech was thought levity. Her thyroid cancer journey inspired her and her friends to collect funds, which she presented in support of ITOG’s mission. This generous donation is greatly appreciated by all ITOG members. These women filled the evening with inspiration and gave meaning to our meeting and our mission at the ITOG.</div></div><div><div> </div><div>The Annual Meeting offers an opportunity for ITOG members to get to know each other and to share cutting-edge science, facilitating opportunities for innovation and discovery with colleagues. It is a time to reflect, to be inspired, and to forge novel collaborations across disciplines and even countries. Overall, attendees found the meeting to be a joyful, memorable, and educational experience. We look forward to our 14th Annual Meeting, which will be hosted by Dr. Sophie Leboulleux and her team in Paris, France at the Institut Gustave Roussy from May 13-15, 2020. </div></div><div> </div><div> </div><div> </div>]]></description><category>Annual Meeting</category><pubDate>Sun, 20 Oct 2019 01:03:00 GMT</pubDate></item><item><title>ITOG Board of Directors Announces a New International Board Member</title><link>https://itog.org/news/473633/</link><guid>https://itog.org/news/473633/</guid><description><![CDATA[ITOG is pleased to announce that Dr. Sophie Leboulleux has been elected as the newest international member of the ITOG Board of Directors. Sophie Leboulleux is board certified in endocrinology, nuclear medicine and oncology. She works in the Department of Nuclear Medicine and Endocrine Oncology in Villejuif, France where she is responsible for the Thyroid Cancer Multidisciplinary Team. Her current clinical interests include treatment and follow up of thyroid cancer from thyroid nodule to radioactive iodine refractory thyroid cancer and imaging of cancer with TEP. Her current research is focused on the role of adjuvant radioactive treatment administration and on radioactive refractory thyroid cancer. She leads a prospective randomized study on the utility of postoperative radioactive iodine treatment, a prospective study on redifferentiation and has been co-investigator for trials in radioactive iodine refractory differentiated thyroid cancer and medullary thyroid cancer. She is Associate Professor, Chief of the Department of Nuclear Medicine in Villejuif and Associate Professor in the Department of Endocrine Oncology. ITOG is fortunate to have such qualified individuals to serve on the board of directors, ensuring commitment to the mission of ITOG in catalyzing effective treatments for thyroid cancer.The Board of Directors would like to extend its thanks to Cosimo Durante, MD, PhD University of Rome, Sapienza, Rome, Italy and Christine Spitzweg, MD, University Hospital Munich, Ludwig-Maximilians-University, Munich for standing for election, their level of commitment to ITOG is remarkable and is a source of inspiration for all.]]></description><category>News</category><pubDate>Fri, 11 Oct 2019 17:33:42 GMT</pubDate></item></channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
http://www.feedvalidator.org/check.cgi?url=https%3A//itog.org/resource/rss/news.rss
